Summary
Gilead Sciences, Inc. (GILD) has officially completed its acquisition of Myogen, Inc. through a cash tender offer followed by a merger. This strategic move, finalized on November 17, 2006, integrates Myogen, a bio-pharmaceutical company focused on cardiovascular therapeutics, into Gilead's operations. The acquisition was executed at $52.50 per share, with Gilead providing the necessary funds to acquire all outstanding shares of Myogen. This acquisition represents a significant expansion for Gilead into the cardiovascular disease treatment space, adding Myogen's pipeline and expertise. While the immediate financial statements and pro forma information related to the acquisition will be filed later, the completion of the merger marks a key milestone for Gilead, signaling its intent to broaden its therapeutic portfolio and market reach.
Key Highlights
- 1Gilead Sciences, Inc. has successfully completed the acquisition of Myogen, Inc. through a tender offer and subsequent merger.
- 2The acquisition was finalized on November 17, 2006.
- 3Myogen, Inc. is a bio-pharmaceutical company focused on developing therapeutics for cardiovascular disorders.
- 4The transaction involved a cash payment of $52.50 per share for Myogen's common stock.
- 5The merger resulted in Myogen becoming a wholly-owned subsidiary of Gilead Sciences, Inc.
- 6Gilead exercised a 'top up' option to ensure a short-form merger could be achieved.
- 7Full financial statements and pro forma information for the acquired business will be filed by amendment at a later date.